INSR and endometrial cancer: It has been reported that visfatin upregulated the expression of insulin receptor (IR) and insulin receptor substrate (IRS) 1/2, both of which cooperated with insulin to activate the PI3K/Akt and MAPK/ERK1/2 signaling pathways, thereby promoting proliferation of endometrial cancer cell and inhibiting apoptosis in EC.